MA43816A - Protéines de liaison inductibles et méthodes d'utilisation - Google Patents

Protéines de liaison inductibles et méthodes d'utilisation

Info

Publication number
MA43816A
MA43816A MA043816A MA43816A MA43816A MA 43816 A MA43816 A MA 43816A MA 043816 A MA043816 A MA 043816A MA 43816 A MA43816 A MA 43816A MA 43816 A MA43816 A MA 43816A
Authority
MA
Morocco
Prior art keywords
inductible
methods
binding proteins
proteins
binding
Prior art date
Application number
MA043816A
Other languages
English (en)
Inventor
Patrick Baeuerle
Robert B Dubridge
Luke Evnin
Jeanmarie Guenot
Anand Panchal
Maia Vinogradova
Holger Wesche
Original Assignee
Maverick Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maverick Therapeutics Inc filed Critical Maverick Therapeutics Inc
Publication of MA43816A publication Critical patent/MA43816A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA043816A 2016-03-08 2017-03-08 Protéines de liaison inductibles et méthodes d'utilisation MA43816A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662305092P 2016-03-08 2016-03-08

Publications (1)

Publication Number Publication Date
MA43816A true MA43816A (fr) 2018-11-28

Family

ID=59789722

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043816A MA43816A (fr) 2016-03-08 2017-03-08 Protéines de liaison inductibles et méthodes d'utilisation

Country Status (14)

Country Link
US (1) US20180134789A1 (fr)
EP (1) EP3426689A4 (fr)
JP (3) JP7195927B2 (fr)
KR (2) KR102501921B1 (fr)
CN (1) CN109071667A (fr)
AU (1) AU2017229687A1 (fr)
BR (1) BR112018068189A2 (fr)
CA (1) CA3016165A1 (fr)
IL (1) IL261432B2 (fr)
MA (1) MA43816A (fr)
MX (1) MX2018010824A (fr)
SG (1) SG11201807548SA (fr)
TW (2) TW202302631A (fr)
WO (1) WO2017156178A1 (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2889906T3 (es) 2015-05-21 2022-01-14 Harpoon Therapeutics Inc Proteínas de unión triespecíficas y usos médicos
PT3377103T (pt) 2015-11-19 2021-05-26 Revitope Ltd Complementação de fragmento de anticorpo funcional para um sistema de dois componentes para exterminação redirecionada de células indesejadas
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
PT3461261T (pt) 2016-05-20 2025-07-31 Harpoon Therapeutics Inc Proteínas de ligação ao cd3 de fragmento variável de cadeia única
CA3024723A1 (fr) 2016-05-20 2017-11-23 Robert B. Dubridge Proteine de liaison a l'albumine serique a domaine unique
MX2019003899A (es) 2016-10-07 2019-08-14 Tcr2 Therapeutics Inc Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion.
KR20190087539A (ko) 2016-11-23 2019-07-24 하푼 테라퓨틱스, 인크. Psma 표적화 삼중특이성 단백질 및 사용 방법
EP3544997A4 (fr) 2016-11-23 2020-07-01 Harpoon Therapeutics, Inc. Protéine de liaison à l'antigène membranaire spécifique de la prostate
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
WO2018160671A1 (fr) * 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inhibiteurs de point de contrôle ciblés et méthodes d'utilisation
WO2018204717A1 (fr) * 2017-05-03 2018-11-08 Harpoon Therapeutics, Inc. Compositions et méthodes pour thérapies par cellules adoptives
BR112019023855B1 (pt) 2017-05-12 2021-11-30 Harpoon Therapeutics, Inc Proteínas de ligação à mesotelina
CN115028727A (zh) 2017-05-12 2022-09-09 哈普恩治疗公司 靶向msln的三特异性蛋白质及使用方法
IL273119B2 (en) * 2017-09-08 2023-10-01 Maverick Therapeutics Inc Binding proteins are activated under limited conditions
JP2020534811A (ja) 2017-09-08 2020-12-03 マベリック セラピューティクス， インコーポレイテッドＭａｖｅｒｉｃｋ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｆｃ領域を含有する条件的に活性化された結合部分
JP7084990B2 (ja) 2017-10-13 2022-06-15 ハープーン セラピューティクス，インク． 三重特異性タンパク質と使用方法
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
WO2019089472A1 (fr) 2017-11-01 2019-05-09 Nantbio, Inc. Voie emt bloquant l'iinterleukine 8 et maîtrisant les cellules souches cancéreuses
CN110218253B (zh) * 2018-03-02 2020-12-04 广西医科大学 抗CD3的纳米抗体CD3/Nb14及其制备方法与应用
CN110218256B (zh) * 2018-03-02 2020-12-08 广西医科大学 抗CD3的纳米抗体CD3/Nb29及其制备方法与应用
WO2019222283A1 (fr) * 2018-05-14 2019-11-21 Harpoon Therapeutics, Inc. Fraction de liaison pour l'activation conditionnelle de molécules d'immunoglobuline
US20210269530A1 (en) * 2018-05-14 2021-09-02 Harpoon Therapeutics, Inc. Conditionally activated binding protein comprising a sterically occluded target binding domain
DK3794024T5 (da) 2018-05-14 2024-08-19 Werewolf Therapeutics Inc Aktiverbare interleukin-2 polypeptider og fremgangsmåder til anvendelse heraf
EP3794023A1 (fr) 2018-05-14 2021-03-24 Werewolf Therapeutics, Inc. Polypeptides d'interleukine 12 activables et procédés d'utilisation associés
US11634467B2 (en) * 2018-06-22 2023-04-25 Cugene Inc. Cytokine-based bioactivatable drugs and methods of uses thereof
US20210309756A1 (en) 2018-08-09 2021-10-07 Maverick Therapeutics, Inc. Coexpression and purification method of conditionally activated binding proteins
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN113286817B (zh) * 2018-09-25 2025-01-28 哈普恩治疗公司 Dll3结合蛋白及使用方法
EP3917542A4 (fr) * 2019-01-29 2023-03-08 Gritstone bio, Inc. Protéines de liaison multispécifiques
AU2020231391A1 (en) * 2019-03-05 2021-10-28 Takeda Pharmaceutical Company Limited Conditionally activated binding proteins containing Fc regions and moieties targeting tumor antigens
EP4592313A3 (fr) 2019-03-05 2025-11-19 Takeda Pharmaceutical Company Limited Protéines de liaison à activation conditionnelle restreinte
MX2021013766A (es) 2019-05-14 2022-02-21 Werewolf Therapeutics Inc Restos de separacion y metodos de uso de los mismos.
US12516128B2 (en) 2019-05-14 2026-01-06 Harpoon Therapeutics, Inc. EpCAM binding proteins and methods of use
WO2021097060A1 (fr) * 2019-11-13 2021-05-20 Harpoon Therapeutics, Inc. Molécule pro-immunomodulatrice comprenant une fraction de groupement
AU2020384375A1 (en) 2019-11-14 2022-05-26 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
WO2021119516A1 (fr) * 2019-12-13 2021-06-17 Cugene Inc. Médicaments bioactivables à base de cytokine et procédés d'utilisations associés
EP4045541A4 (fr) * 2019-12-20 2023-08-16 Shandong Boan Biotechnology Co., Ltd. Bras anti-cd3 optimisé dans la génération d'anticorps bispécifiques à des lymphocytes t pour l'immunothérapie
EP4090686A4 (fr) * 2020-01-17 2024-03-27 Immune Targeting Inc. Pro-anticorps réduisant la toxicité hors cible
US20210301015A1 (en) * 2020-01-17 2021-09-30 Aetio Biotherapy, Inc. Pro-antibody that reduces off-target toxicity
IL295448A (en) 2020-02-21 2022-10-01 Harpoon Therapeutics Inc flt3 binding proteins and methods of use
MX2022011780A (es) 2020-04-09 2022-11-10 Cytomx Therapeutics Inc Composiciones que contienen anticuerpos activables.
CN115698072B (zh) 2020-07-01 2023-07-04 山东博安生物技术股份有限公司 抗gpc3抗体，抗gpc3嵌合抗原受体和gpc3/cd3双特异性抗体
WO2022006562A1 (fr) 2020-07-03 2022-01-06 Dana-Farber Cancer Institute, Inc. Anticorps anti-coronavirus multispécifiques
AR123266A1 (es) 2020-08-17 2022-11-16 Maverick Therapeutics Inc Proteínas de unión limitadas activadas de forma condicional
JP2023545347A (ja) * 2020-08-18 2023-10-30 オンチレス・ファーマ・インコーポレイテッド 改変セリンプロテアーゼプロタンパク質
IL300080A (en) 2020-08-18 2023-03-01 Onchilles Pharma Inc Processed porcine pancreatic elastase proteins
US11617767B2 (en) 2020-11-20 2023-04-04 Simcere Innovation, Inc. Armed dual CAR-T compositions and methods for cancer immunotherapy
US11555078B2 (en) 2020-12-09 2023-01-17 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting PSMA and effector cell antigens
WO2022214978A1 (fr) 2021-04-06 2022-10-13 Takeda Pharmaceutical Company Limited Méthodes thérapeutiques utilisant des protéines de liaison activées de manière conditionnelle contraintes
EP4334354A1 (fr) 2021-05-06 2024-03-13 Dana-Farber Cancer Institute, Inc. Anticorps anti-alk et leurs procédés d'utilisation
US20240415919A1 (en) 2021-08-31 2024-12-19 Dana-Farber Cancer Institute, Inc. Compositions and methods for treatment of autoimmune disorders and cancer
CA3238936A1 (fr) 2021-11-24 2023-06-01 Wayne A. Marasco Anticorps contre ctla-4 et leurs methodes d'utilisation
US20250051472A1 (en) 2021-12-17 2025-02-13 Dana-Farber Cancer Institute, Inc. Antibodies and uses thereof
WO2023114543A2 (fr) 2021-12-17 2023-06-22 Dana-Farber Cancer Institute, Inc. Plateforme pour découverte d'anticorps
WO2024039672A2 (fr) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Anticorps anti-mlsn et leurs méthodes d'utilisation
AU2023324667A1 (en) 2022-08-15 2025-02-13 Dana-Farber Cancer Institute, Inc. Antibodies against cldn4 and methods of use thereof
JP2025537782A (ja) * 2022-11-15 2025-11-20 エフ． ホフマン－ラ ロシュ アーゲー 活性化可能なエフェクタードメインを有する組換え結合タンパク質
WO2025237931A1 (fr) * 2024-05-15 2025-11-20 F. Hoffmann-La Roche Ag Protéines de liaison recombinantes avec lymphocytes t activables de manière conditionnelle et domaines effecteurs recrutant des cellules nk

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501621A (ja) * 2003-05-31 2008-01-24 マイクロメット アクツィエン ゲゼルシャフト Ｂ細胞関連疾患を処置するための二重特異性抗ｃｄ３、抗ｃｄ１９抗体構築物を含む薬学的組成物
JP4948174B2 (ja) * 2003-10-16 2012-06-06 マイクロメット アクツィエン ゲゼルシャフト 多重特異的脱免疫ｃｄ３−結合物質
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
RU2013110876A (ru) 2010-08-24 2014-09-27 Рош Гликарт Аг Активируемые биспецифические антитела
US20120225081A1 (en) 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
CN107827985A (zh) * 2011-05-21 2018-03-23 宏观基因有限公司 能够与人和非人cd3结合的cd3结合分子
RU2014103288A (ru) 2011-07-01 2015-08-10 Байер Интеллектчуал Проперти Гмбх Слитые полипептиды релаксина и их применение
PH12021553014A1 (en) 2012-02-27 2022-09-05 Ablynx Nv Cx3cr1-binding polypeptides
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
MX353382B (es) 2012-03-01 2018-01-10 Amgen Res Munich Gmbh Moleculas de union polipeptido de larga duracion.
WO2014004549A2 (fr) 2012-06-27 2014-01-03 Amgen Inc. Protéines de liaison anti-mésothéline
CN105431524B (zh) * 2013-06-10 2020-04-21 达娜-法勃肿瘤研究所公司 用于降低肿瘤细胞的免疫抑制的方法和组合物
KR102497443B1 (ko) * 2014-03-28 2023-02-08 젠코어 인코포레이티드 Cd38 및 cd3에 결합하는 이중특이적 항체
PT3377103T (pt) 2015-11-19 2021-05-26 Revitope Ltd Complementação de fragmento de anticorpo funcional para um sistema de dois componentes para exterminação redirecionada de células indesejadas
US20210309756A1 (en) * 2018-08-09 2021-10-07 Maverick Therapeutics, Inc. Coexpression and purification method of conditionally activated binding proteins

Also Published As

Publication number Publication date
EP3426689A1 (fr) 2019-01-16
IL261432A (en) 2018-10-31
KR20180120245A (ko) 2018-11-05
RU2018134949A3 (fr) 2020-08-14
KR102501921B1 (ko) 2023-02-21
CN109071667A (zh) 2018-12-21
JP2023123519A (ja) 2023-09-05
JP2022140856A (ja) 2022-09-28
RU2018134949A (ru) 2020-04-08
CA3016165A1 (fr) 2017-09-14
SG11201807548SA (en) 2018-09-27
BR112018068189A2 (pt) 2019-02-05
EP3426689A4 (fr) 2020-01-15
TW201808990A (zh) 2018-03-16
MX2018010824A (es) 2019-05-15
TW202302631A (zh) 2023-01-16
KR20230041739A (ko) 2023-03-24
US20180134789A1 (en) 2018-05-17
JP2019513014A (ja) 2019-05-23
IL261432B1 (en) 2023-11-01
WO2017156178A1 (fr) 2017-09-14
JP7195927B2 (ja) 2022-12-26
IL261432B2 (en) 2024-03-01
JP7293456B2 (ja) 2023-06-19
AU2017229687A1 (en) 2018-09-20

Similar Documents

Publication Publication Date Title
MA43816A (fr) Protéines de liaison inductibles et méthodes d'utilisation
EP3442991A4 (fr) Peptides de liaison à ras et méthodes d'utilisation
EP3355920A4 (fr) Protéines de liaison à pd-1 et leurs méthodes d'utilisation
EP3694529A4 (fr) Protéines trispécifiques et méthodes d'utilisation
EP3802581A4 (fr) Protéines de liaison multispécifiques et améliorations de celles-ci
IL281683A (en) Dll3 binding proteins and methods of use
MA47113A (fr) Protéines de liaison à l'antigène anti- neuropiline et leurs méthodés d'utilisation
EP3678731A4 (fr) Soupapes hémostatiques et méthodes d'utilisation
EP3684361A4 (fr) Inhibiteurs substitués de ménine-mll et méthodes d'utilisation
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
EP3429591A4 (fr) Inhibiteurs substitués de ménine-mll et méthodes d'utilisation
IL261666A (en) Related proteins and methods of using them
EP3337517A4 (fr) Conjugués anticorps-médicaments anti-dll3 et méthodes d'utilisation
EP3500594A4 (fr) Anticorps, fragments de liaison, et procédés d'utilisation
EP3655432A4 (fr) Protéines de liaison 1
MA42243A (fr) Anticorps de facteur xi et méthodes d'utilisation
EP3393382A4 (fr) Couteau ophtalmique et méthodes d'utilisation
EP3317273A4 (fr) Inhibiteurs d'egfr et méthodes d'utilisation de ceux-ci
EP3423451A4 (fr) Inhibiteurs de la liaison protéine wdr5-protéine
EP3402549A4 (fr) Compositions pour micro-aiguilles et méthodes d'utilisation de celles-ci
EP3551209A4 (fr) Fusions d'insuline-fc et méthodes d'utilisation
MA48579A (fr) Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
MA42542A (fr) Molécules se liant à pd-1 et méthodes d'utilisation correspondantes
EP3426298A4 (fr) Molécules de liaison à l'ilt7 et leurs méthodes d'utilisation
EP3319611A4 (fr) Oxystérols et leurs méthodes d'utilisation